What is WhiteSwell?
WhiteSwell is a specialized medical technology firm dedicated to transforming the treatment landscape for acute decompensated heart failure (ADHF). The company's core innovation, the eLym System, represents a paradigm shift in how clinicians manage tissue congestion. By targeting the thoracic duct outlet to enhance lymphatic system function, WhiteSwell provides a therapeutic alternative for patients who remain symptomatic despite standard diuretic interventions. This focus on lymphatic decongestion positions the company as a high-growth player within the cardiovascular device market, offering a novel solution to a persistent clinical challenge.
How much funding has WhiteSwell raised?
WhiteSwell has raised a total of $30M across 1 funding round:
Series B
$30M
Series B (2018): $30M with participation from RA Capital Management
Key Investors in WhiteSwell
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing drugs, medical devices, diagnostics, and research tools.
What's next for WhiteSwell?
With the successful closure of this major strategic investment, WhiteSwell is well-positioned to accelerate its clinical trial programs and refine its commercialization strategy. The company's roadmap likely involves scaling its manufacturing capabilities and expanding its clinical evidence base to support regulatory submissions. By leveraging its current financial runway, WhiteSwell aims to solidify its market position as a leader in lymphatic-based heart failure therapies, ultimately seeking to improve long-term patient outcomes and reduce hospital readmission rates. The focus remains on executing key milestones that will demonstrate the efficacy and safety of the eLym System in broader patient populations.
See full WhiteSwell company page
